X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES CIPLA JUBILANT LIFE SCIENCES/
CIPLA
 
P/E (TTM) x 20.1 44.1 45.6% View Chart
P/BV x 4.3 3.6 117.6% View Chart
Dividend Yield % 0.4 0.4 120.5%  

Financials

 JUBILANT LIFE SCIENCES   CIPLA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
CIPLA
Mar-17
JUBILANT LIFE SCIENCES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs187622 30.0%   
Low Rs65458 14.2%   
Sales per share (Unadj.) Rs364.3181.9 200.4%  
Earnings per share (Unadj.) Rs6.812.9 53.2%  
Cash flow per share (Unadj.) Rs24.529.3 83.6%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %2.40.4 643.2%  
Book value per share (Unadj.) Rs164.9155.7 105.9%  
Shares outstanding (eoy) m159.28804.51 19.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 11.6%   
Avg P/E ratio x18.442.0 43.8%  
P/CF ratio (eoy) x5.118.4 27.9%  
Price / Book Value ratio x0.83.5 22.0%  
Dividend payout %43.815.5 282.0%   
Avg Mkt Cap Rs m20,061434,516 4.6%   
No. of employees `0006.223.0 26.8%   
Total wages/salary Rs m11,05226,338 42.0%   
Avg. sales/employee Rs Th9,383.06,349.1 147.8%   
Avg. wages/employee Rs Th1,786.91,143.0 156.3%   
Avg. net profit/employee Rs Th176.3449.3 39.2%   
INCOME DATA
Net Sales Rs m58,034146,302 39.7%  
Other income Rs m1912,287 8.3%   
Total revenues Rs m58,224148,589 39.2%   
Gross profit Rs m5,78624,758 23.4%  
Depreciation Rs m2,81213,229 21.3%   
Interest Rs m3,2371,594 203.1%   
Profit before tax Rs m-7212,222 -0.6%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,798 38.7%   
Profit after tax Rs m1,09010,354 10.5%  
Gross profit margin %10.016.9 58.9%  
Effective tax rate %-965.914.7 -6,566.9%   
Net profit margin %1.97.1 26.5%  
BALANCE SHEET DATA
Current assets Rs m29,28087,370 33.5%   
Current liabilities Rs m38,91233,081 117.6%   
Net working cap to sales %-16.637.1 -44.7%  
Current ratio x0.82.6 28.5%  
Inventory Days Days8487 97.0%  
Debtors Days Days5162 81.3%  
Net fixed assets Rs m55,712111,567 49.9%   
Share capital Rs m1551,609 9.6%   
"Free" reserves Rs m20,968123,645 17.0%   
Net worth Rs m26,265125,254 21.0%   
Long term debt Rs m17,16936,454 47.1%   
Total assets Rs m88,606209,532 42.3%  
Interest coverage x1.08.7 11.3%   
Debt to equity ratio x0.70.3 224.6%  
Sales to assets ratio x0.70.7 93.8%   
Return on assets %4.95.7 85.7%  
Return on equity %4.28.3 50.2%  
Return on capital %11.68.5 136.1%  
Exports to sales %37.834.2 110.5%   
Imports to sales %16.58.3 197.7%   
Exports (fob) Rs m21,93350,050 43.8%   
Imports (cif) Rs m9,56712,203 78.4%   
Fx inflow Rs m22,00451,066 43.1%   
Fx outflow Rs m11,74917,678 66.5%   
Net fx Rs m10,25533,388 30.7%   
CASH FLOW
From Operations Rs m8,02623,824 33.7%  
From Investments Rs m-1,744-13,127 13.3%  
From Financial Activity Rs m-4,447-13,239 33.6%  
Net Cashflow Rs m1,834-2,478 -74.0%  

Share Holding

Indian Promoters % 45.6 16.0 285.0%  
Foreign collaborators % 3.5 20.8 16.8%  
Indian inst/Mut Fund % 8.7 12.2 71.3%  
FIIs % 21.2 23.7 89.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 21.1 26.2 80.5%  
Shareholders   23,815 161,166 14.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Impacted by one offs (Quarterly Results Update - Detailed)

Jun 2, 2016

Cipla has announced its 4QFY16 results. The company has reported 7.6% YoY growth in sales and a decline of 68.9% YoY in net profits. Here is our analysis of the results.

Cipla: Quarter Impacted by One-Offs (Quarterly Results Update - Detailed)

Apr 6, 2016

Cipla has announced its 3QFY16 results. The company has reported 15.3% YoY and 4.7% YoY growth in sales and net profits respectively.

Cipla: Domestic business underperforms (Quarterly Results Update - Detailed)

Feb 12, 2016

Cipla has announced its 2QFY16 results. The company has reported 27.8% YoY and 44.3% YoY growth in sales and net profits respectively. Here is our analysis of the results.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 18, 2017 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - WYETH LTD COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS